KYTHERA BIOPHARMACEUTICALS INC 4
4 · KYTHERA BIOPHARMACEUTICALS INC · Filed Oct 2, 2015
Insider Transaction Report
Form 4
David Nathaniel E
Director
Transactions
- Disposition to Issuer
Stock Option (right to buy)
2015-10-01−5,672→ 0 totalExercise: $16.00Exp: 2022-10-10→ Common Stock (5,672 underlying) - Disposition to Issuer
Stock Option (right to buy)
2015-10-01−1,512→ 0 totalExercise: $4.84Exp: 2019-01-21→ Common Stock (1,512 underlying) - Disposition to Issuer
Stock Option (right to buy)
2015-10-01−8,400→ 0 totalExercise: $33.26Exp: 2024-06-05→ Common Stock (8,400 underlying) - Disposition to Issuer
Common Stock
2015-10-01−429,874→ 0 total - Disposition to Issuer
Stock Option (right to buy)
2015-10-01−9,832→ 0 totalExercise: $4.84Exp: 2019-09-17→ Common Stock (9,832 underlying) - Disposition to Issuer
Stock Option (right to buy)
2015-10-01−6,618→ 0 totalExercise: $21.65Exp: 2023-06-04→ Common Stock (6,618 underlying) - Disposition to Issuer
Stock Option (right to buy)
2015-10-01−11,591→ 0 totalExercise: $53.26Exp: 2025-06-02→ Common Stock (11,591 underlying)
Footnotes (3)
- [F1]Disposed of pursuant to the Amended and Restated Agreement and Plan of Merger dated as of August 4, 2015 (the "Merger Agreement"), by and among Allergan plc (formerly known as Actavis plc) ("Allergan"), Keto Merger Sub, Inc. (a wholly owned subsidiary of Allergan) and Issuer, whereby each share of Issuer common stock was canceled in exchange for $75.00 in cash, without interest.
- [F2]Reflects a transfer of 30,286 shares exempt under Section 16a-12 since the Reporting Person's last ownership report.
- [F3]Pursuant to the Merger Agreement, each option to purchase common stock was canceled and paid in cash assuming a stock price of $75.00.